中超控股(002471.SZ):深圳鑫騰華完成轉讓2.536億股 第一大股東變更為中超集團
格隆匯11月10日丨中超控股(002471.SZ)公佈,公司今日獲悉深圳鑫騰華被強制轉讓給王一妮、陳華、張傑、徐福榮、錢建忠的2.536億股公司股票已於2020年10月30日在中國證券登記結算有限責任公司深圳分公司完成了過户登記手續,並於2020年11月2日收到中國證券登記結算有限責任公司深圳分公司出具的《證券過户登記確認書》。
上述權益變動後,公司第一大股東由深圳鑫騰華變更為中超集團;控股股東及實際控制人未發生變更,控股股東仍為中超集團,實際控制人仍為楊飛,中超集團及其一致行動人楊飛持有公司股份2.29億股,佔公司總股本的18.06%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.